+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019

  • ID: 4900117
  • Drug Pipelines
  • December 2019
  • Region: Global
  • 48 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • CJ HealthCare Corp
  • MorphoSys AG
  • Novopyxis Inc
  • Vicore Pharma AB
  • MORE
Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019

Summary

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.

Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 9 molecules. Out of which approximately 7 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.

The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H2 2019, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • The report reviews Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • CJ HealthCare Corp
  • MorphoSys AG
  • Novopyxis Inc
  • Vicore Pharma AB
  • MORE
Introduction
Report Coverage
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Overview
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Companies Involved in Therapeutics Development
CJ HealthCare Corp
KinDex Pharmaceuticals Inc
MorphoSys AG
Novopyxis Inc
Vicore Pharma AB
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Drug Profiles
(amlodipine besylate + valsartan) + atorvastatin calcium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NP-6A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AGTR2 for Skin Inflammation and Inflammatory Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize AGTR2 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Dormant Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Discontinued Products
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Product Development Milestones
Featured News & Press Releases
Oct 01, 2019: Update on progress in clinical lead program VP01 (C21)
Sep 06, 2019: Safe and well tolerated dose of C21 established in successful dose escalation phase 1 study
Apr 23, 2019: Vicore Pharma announces systemic sclerosis as the second indication for VP01
Sep 10, 2018: Vicore Pharma expands VP01 (C21) clinical program to enable functional read out
Apr 18, 2018: Vicore Pharma receives approval to start Phase IIa study in IPF
Mar 21, 2018: Frontiers in Physiology publish data with C21 on pulmonary fibrosis
Jan 26, 2018: Highlights from new publications on C21 and the AT2 receptor
Dec 22, 2017: Vicore Pharma has submitted an application to start a phase II study for Idiopathic Pulmonary Fibrosis
Oct 09, 2017: Clinical Potential of C21 Highlighted in Review Publications
Oct 02, 2017: Phase I extension study demonstrates beneficial effects on lipid metabolism with C21
Aug 17, 2017: Results from Extension Study with C21 Show Safety, Tolerability and Indicate Effects on lipid Metabolism
May 19, 2017: MorphoSys Announces First Results from Phase 1 Study with Lanthipeptide MOR107 in Healthy Volunteers
Mar 08, 2017: C21 has a strong impact on several markers in an in vitro study for pulmonary fibrosis
Mar 03, 2017: New positive study results on diabetic nephropathy with Vicore Pharma's candidate drug C21
Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by CJ HealthCare Corp, H2 2019
Pipeline by KinDex Pharmaceuticals Inc, H2 2019
Pipeline by MorphoSys AG, H2 2019
Pipeline by Novopyxis Inc, H2 2019
Pipeline by Vicore Pharma AB, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019

List of Figures
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • CJ HealthCare Corp
  • KinDex Pharmaceuticals Inc
  • MorphoSys AG
  • Novopyxis Inc
  • Vicore Pharma AB
Note: Product cover images may vary from those shown
Adroll
adroll